Literature DB >> 27337230

Management of Calvarial Tumors: A Retrospective Analysis and Literature Review.

Erkin Ozgiray1, Karthikeyan Perumal, Celal Cinar, Kadir Emre Caliskan, Yesim Ertan, Taskin Yurtseven, Nezih Oktar, Izzet Ovul, Kazim Oner.   

Abstract

AIM: Tumors of various organs that metastasize to bone do not neglect calvarium as a target. The aim of this study was to characterize the calvarial tumors.
MATERIAL AND METHODS: We retrospectively reviewed 45 consecutive patients operated for calvarial masses from January 2002 till May 2012 at our hospital. Skull base tumors and patients ≤18 years were excluded.
RESULTS: Three groups of lesions were found - calvarial metastases (15/45), primary tumors (5/45) and tumor-like lesions (25/45). Malignant lesions were equitable by gender distribution, higher age of onset (median age of primary =55; secondary = 60 years) and benign lesions by younger age (median = 35) and female bias (18/25). Calvarial metastases mostly presented with local swelling (10/15), local pain (6/15) and rarely neurologic deficit. There was associated dural sinus thrombosis (4/20 of malignant; 1/25 of benign lesions) and osteolysis (3/5 primary malignant, 13/15 secondary and 18/25 of benign lesions). Complete surgical excision was possible with minimal morbidity in all except one patient and nil mortality.
CONCLUSION: Nearly half (20/45) of the calvarial lesions tend to be malignant with most of them presenting as silent painless masses. Surgical excision should be considered only after suitable investigation and appropriate neurosurgical set-up.

Entities:  

Mesh:

Year:  2016        PMID: 27337230     DOI: 10.5137/1019-5149.JTN.12537-15.0

Source DB:  PubMed          Journal:  Turk Neurosurg        ISSN: 1019-5149            Impact factor:   1.003


  1 in total

Review 1.  Calvarial lesions: overview of imaging features and neurosurgical management.

Authors:  Isabella Nasi-Kordhishti; Johann-Martin Hempel; Florian Heinrich Ebner; Marcos Tatagiba
Journal:  Neurosurg Rev       Date:  2021-03-22       Impact factor: 3.042

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.